Deal Details

Taysha Completes $230.0 Million Follow-On Offering

Healthcare

Taysha follow-on offering

Summary

Taysha Gene Therapies, Inc. (“Taysha” or the “Company”) (NASDAQ: TSHA) recently completed the pricing of an underwritten public offering (the “Offering”) of 37,500,001 shares of its common stock, including 5,000,000 shares sold pursuant to full exercise of the underwriters’ option to purchase additional shares, at a price of $6.00 per share and 833,333 pre-funded warrants at a price of $5.999 per pre-funded warrant, generating gross proceeds of approximately $230.0 million.

Baird served as lead manager on this Offering.

About

Taysha is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. Taysha is headquartered in Dallas, Texas.

Healthcare

Taysha follow-on offering